Keymed Biosciences Inc.

SZSC:2162 Stock Report

Market Cap: HK$8.8b

Keymed Biosciences Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Bo Chen

Chief executive officer

CN¥4.8m

Total compensation

CEO salary percentage95.9%
CEO tenure3.7yrs
CEO ownershipn/a
Management average tenure4.3yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bo Chen's remuneration changed compared to Keymed Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥743m

Mar 31 2024n/an/a

-CN¥551m

Dec 31 2023CN¥5mCN¥5m

-CN¥359m

Sep 30 2023n/an/a

-CN¥313m

Jun 30 2023n/an/a

-CN¥267m

Mar 31 2023n/an/a

-CN¥287m

Dec 31 2022CN¥4mCN¥4m

-CN¥308m

Sep 30 2022n/an/a

-CN¥281m

Jun 30 2022n/an/a

-CN¥253m

Mar 31 2022n/an/a

-CN¥2b

Dec 31 2021CN¥4mCN¥4m

-CN¥4b

Sep 30 2021n/an/a

-CN¥4b

Jun 30 2021n/an/a

-CN¥4b

Mar 31 2021n/an/a

-CN¥3b

Dec 31 2020CN¥231kCN¥227k

-CN¥819m

Dec 31 2019CN¥188kCN¥183k

-CN¥168m

Compensation vs Market: Bo's total compensation ($USD656.02K) is above average for companies of similar size in the Hong Kong market ($USD478.94K).

Compensation vs Earnings: Bo's compensation has increased whilst the company is unprofitable.

CEO

Bo Chen (49 yo)

3.7yrs

Tenure

CN¥4,788,000

Compensation

Dr. Bo Chen has been executive Director, chairman of Board and chief executive officer at Keymed Biosciences Inc. since April 03, 2021 and served as Director since April 23, 2018 until April 03, 2021. Dr....

Leadership Team

NamePositionTenureCompensationOwnership
Bo Chen
Executive Chairman & CEO3.7yrsCN¥4.79mno data
Gang Xu
Senior VP & Executive Director3.7yrsCN¥1.61mno data
Changyun Wang
Senior VP & Executive Director6.6yrsCN¥2.81mno data
Qi Chen
Senior VP & Non Executive Director6.8yrsCN¥178.00kno data
Yanrong Zhang
CFO, VP & Joint Company Secretary4.3yrsno datano data
Qian Jia
Senior Vice President6.8yrsno datano data
Pak Yu Tam
Joint Company Secretary2.8yrsno datano data

4.3yrs

Average Tenure

49yo

Average Age

Experienced Management: 2162's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bo Chen
Executive Chairman & CEO6.7yrsCN¥4.79mno data
Gang Xu
Senior VP & Executive Director6.5yrsCN¥1.61mno data
Changyun Wang
Senior VP & Executive Director3.8yrsCN¥2.81mno data
Qi Chen
Senior VP & Non Executive Director6.5yrsCN¥178.00kno data
Cheuk Kin Law
Independent Non Executive Director3.7yrsCN¥572.00kno data
Yang Ke
Independent Non Executive Director3.7yrsCN¥476.00kno data
Xiao-Fan Wang
Independent Non-Executive Director3.7yrsCN¥476.00kno data
Yilun Liu
Non Executive Director3.8yrsno datano data
Min Chuan Wang
Non Executive Director3.8yrsno datano data

3.8yrs

Average Tenure

49yo

Average Age

Experienced Board: 2162's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 12:27
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Keymed Biosciences Inc. is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin ZhangChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited
Wangbin ZhouChina International Capital Corporation Limited